Multiple Sclerosis Drugs - Romania

Romania

Romania's Multiple Sclerosis Drugs market is projected to reach a revenue of US$31.90m in 2024.
The market is expected to show an annual growth rate (CAGR 2024-2028) of 1.45%, resulting in a market volume of US$33.79m by 2028.
In comparison to other countries, United States is expected to generate the highest revenue of US$12,360.00m in 2024.
Romania has seen an increasing demand for innovative multiple sclerosis drugs, driven by a growing awareness of the disease and improved access to healthcare services.

Key regions: South Korea, Brazil, Australia, China, Japan

Market

Region

Region comparison

Currency

Analyst Opinion

The Multiple Sclerosis Drugs market in Romania has been showing a steady growth in recent years.

Customer preferences: Patients suffering from Multiple Sclerosis in Romania tend to prefer disease-modifying therapies over symptomatic treatments. This is in line with the global trend of patients opting for therapies that can modify the course of the disease and slow down its progression.

Trends in the market: The Multiple Sclerosis Drugs market in Romania has been growing at a steady pace due to increasing awareness about the disease and its treatment options. The market is dominated by disease-modifying therapies with a few symptomatic treatments available. The market is also seeing an influx of new therapies that are more effective and have fewer side effects. This trend is expected to continue in the coming years.

Local special circumstances: Romania has a high prevalence of Multiple Sclerosis, which is one of the reasons why the market for Multiple Sclerosis Drugs is growing in the country. The country also has a well-established healthcare system that provides access to treatment for most patients. However, the cost of treatment can be a barrier for some patients, especially those who do not have health insurance.

Underlying macroeconomic factors: The Romanian economy has been growing steadily in recent years, which has led to an increase in healthcare spending. This has had a positive impact on the Multiple Sclerosis Drugs market as more patients are able to afford treatment. The government has also taken steps to improve access to healthcare, which has further boosted the market. However, the country still faces challenges in terms of healthcare infrastructure and access to healthcare in rural areas.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.